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THE PREVELANCE AND RISK FACTORS OF VENTILATOR ASSOCIATED 
PNEUMONIA IN INTENSIVE CARE UNIT IN HOSPITAL SULTANAH BAHIYAH, 
KEDAH MALAYSIA 
 
Dr Loh Sze Yee 
MMed Anaesthesiology 
 
Department of Anaesthesiology and Intensive Care Unit 
School of Medical Sciences, Universiti Sains Malaysia 
Health Campus, 16150 Kelantan, Malaysia 
 
Introduction: Ventilator associated pneumonia (VAP) is the commonest nosocomial 
infection in intensive care unit (ICU). We conducted a first study to collect local data on 
prevalence and risk factors of VAP in Hospital Sultanah Bahiyah (HSB), Kedah. 
 
Methodology: This prospective cohort surveillance was conducted on patients admitted to 
an adult medical-surgical ICU of a tertiary hospital from 1st August 2104 to 31st July 2105. 
VAP was diagnosed using Malaysia Registry of ICU (MRIC) criteria which included clinical 
manifestation, imaging and investigations. 
Results: In total, 297 patients were enrolled in this study. The prevalence of VAP was 
22.0%. The most common causative pathogen was Acinetobacter sp. (31.8%). Multivariate 
analysis using simple logistic regression showed that risk factors for VAP were elderly patients 
(P=0.02; OR 1.02; 95% CI 1.00, 1.04), increase duration of ventilation (P<0.001; OR 1.49; 95% 
CI 1.35, 1.63), length of stay in ICU (P<0.001; OR 1.45; 95% CI 1.33, 1.59), length of stay in 
hospital (P<0.001; OR 1.07; 95% CI 1.04, 1.09), respiratory diseases (P=0.02; OR 2.25; 95% CI 
1.17, 4.33), lung malignancy (P<0.001; OR 22.35; 95% CI 6.24, 80.09), previous antibiotic 
within three months (P=0.02; OR 2.25; 95% CI 1.17, 4.33), tracheostomy (P<0.001; OR 18.42; 
95% CI 9.36, 36.23), reintubation (P<0.001; OR 25.69; 95% CI 12.73, 51.82), transportation for 
remote procedure (P<0.001; OR 20.76; 95% CI 9.65, 44.76), central venous line (CVL) insertion 
(P=0.04; OR 2.22; 95% CI 1.04, 4.76), continuous sedation (P=0.03; OR 1.85; 95% CI 1.04, 
3.26) and without venous thromboprophylaxis (P=0.03; OR 2.05; 95% CI 1.09, 3.87). 
 
Conclusion: The prevalence and risk factors in our study were comparable to national and 
international data. We identify one new risk factor which is CVL insertion. 
 
Dr Laila Abdul Mukmin: Supervisor 
Professor Mahamarowi Omar: Co-Supervisor 
Dr Ahmad Shaltut bin Othman: Co-Supervisor 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Hospital acquired infections or nosocomial infections can be defined as those occurring 
within 48 hours of hospital admission, 3 days of discharge or 30 days of an operation. They 
affect 10% of hospitalized patients and are important causes of morbidity and mortality 
throughout the world (1). The critically ill patients are at particular risk of developing 
intensive care unit (ICU) acquired infection as they were mostly immuno-compromised, 
mechanical ventilated and have multiple invasive procedures done. Nosocomial infections 
can affect multiple sites such as the lungs, urinary tract, surgical sites and the bloodstream. 
Of all the sites, lung is the most vulnerable to develop nosocomial infection. Nosocomial 
pneumonia occurring after 48 hours of mechanical ventilation is referred to as ventilator 
associated pneumonia (VAP). 
 
The incidence of VAP varies from 9% to 27% all over the world. In the United States of 
America it ranges from 9.3% to 15% while in Europe is 8% to 28%. In Asia it was 
documented to be 2% to 40%. In Malaysia, the incidence was found to be 26.5%. The 
mortality rate varies between 30% to 70% (2) and can be as high as 90% in some centers. 
However, not all deaths among affected patients are the direct result of infection;   rather, 
VAP is a marker for severity of illness.  
 
VAP is a common condition but it is difficult to diagnose and expensive to treat. 
Modifiable risk factors for VAP have influence on patient treatment.  Thus with better 
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understanding of the risk factors of VAP and the implementation and awareness of 
ventilator bundle for ventilated patient, the mortality rate can be reduced to 50%. This is 
important as it not only reduces the cost of health care in Malaysia, but also reduces the 
length of stay in ICU. As in Malaysia the ICU bed is always shortage and limited, it is a 
concern that VAP depletes the limited resources in our ICU. 
 
 
The outcome indicators of VAP can be used in benchmarking the quality of patient care in 
Malaysia. Therefore, surveillance of VAP received a high level of attention. Since 2000, 
the Malaysian surveillance has targeted three site-specific, device-associated infections, 
including ventilator-associated pneumonia, central-line-related bloodstream infection (CR-
BSI), and catheter-related urinary tract infection (CR-UTI). The Malaysia Ministry of 
Health, Malaysian Registry of Intensive Care (MRIC) also produces a yearly report and 
recommendation on VAP. MRIC (3, 4) has also outlined and advised VAP bundle for our 
local hospitals.  
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1.2 LITERATURE REVIEW 
 
1.2.1 Ventilator Associated Pneumonia 
 
Ventilator associated pneumonia (VAP) is defined as nosocomial pneumonia occurring in a 
patient after 48 hours of mechanical ventilation via a tracheal or tracheostomy tube (5). 
 
1.2.1.1 Pathogenesis 
 
VAP has been suggested to be related to the interaction between endotracheal tube (ETT), 
host immunity, infecting microorganism and the presence of risk factors. The presence of 
ETT will more or less impaired the cough and gag reflex. This will cause microaspiration 
around the cuff of the ETT. The presence of ETT also caused the mucociliary functions to 
be impaired causing reduction in clearance of the mucous flow and thus increase the chance 
to get VAP. Critically ill patients are mostly immunocompromised as there may be 
impaired of phagocytosis. Furthermore the severity of underlying diseases, the used of 
previous antibiotic and previous surgery will also contribute to lowering the host immunity. 
The infecting microorganism can get access to the lower respiratory tract via 
microaspiration as describe previously. It can also form a biofilm laden with bacteria and 
bacterial colonization within the ETT. Last but not least, the trackling and pooling of 
secretion around the cuff of ETT also plays as a risk factor in VAP. These secretions have 
high bacteria load and subsequently they will have access to the pulmonary parenchyma 
and cause pneumonia. All these microorganisms can be pushed further by the positive 
pressure that is used for in mechanical ventilation. 
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Many risk factors for the development of VAP have been identified. They can be 
differentiated into modifiable and non-modifiable risk factors and into patient-related and 
treatment related risk factors.  
 
Table 1. Risk factors for ventilator-associated pneumonia (6) 
 
Nonmodifiable risk factors 
1. Patient-related risk factor 
• Chronic Obstructive Pulmonry Disease (COPD)    
• Organ System Failure Index of > 2    
• Age of > 60 years     
• Coma     
• Acute Respiratory Distress Syndrome (ARDS)   
• Head trauma     
• Male sex    
2. Intervention-related risk factor 
• Neurosurgery    
• Thoracic surgery   
• Intracranial Pressure (ICP) monitor     
• Transportation out of ICU    
• Reintubation    
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Modifiable risk factors 
1. Intervention-related risk factor 
• Use of H2-antagonist      
• Use of antacids     
• Use of sucralfate    
• 24-h circuit changes, compared with 48-h circuit changes   
• Use of antibiotics    
• Supine position   
• Receive of enteral nutrition  
• Failed subglottic aspiration  
• Intracuff pressure of < 20 cm H2O  
• Tracheostomy 
• Aerosol treatment  
 
It is important to identify the risk factors for VAP as it provides a basis in the 
implementation of prevention strategies. 
 
1.2.1.2 Microbiology 
 
The type of microorganisms that cause VAP can be suspected by the duration of 
mechanical ventilation. Generally, VAP is divided into early onset (within the 1st 4 days) 
and late onset (day 5 onwards). Early onset VAP are usually cause by gram negative 
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bacteria that are sensitive to antibiotic while culprit of the late onset VAP are usually 
microorganisms that have higher level of antibiotic resistant.  
1. Early onset VAP 
 Streptococcus pneumoniae  
 Hemophilus infl uenzae 
 Methicillin-sensitive Staphylo coccus aureus (MSSA) 
 Escherichia coli 
 Klebsiella pneumonia 
 Enterobacter species 
 Proteus species  
 Serratia marcescens 
2. Late onset VAP 
 Methicillin-resistant S. aureus (MRSA) 
 Acinetobacter 
 Pseudomonas aeruginosa,  
 Extended-spectrum beta-lactamase producing bacteria (ESBL) 
 
However the types of multidrug resistant (MDR) organisms are different from hospital to 
hospital. So it is important to know our local microbiological data as the treatment of VAP 
is mainly early empirical antibiotic based on the suspected organism. It can be de-escalated 
once the full culture and sensitivity is available. 
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1.2.1.3 Diagnosis of VAP 
 
Over the years, there have been several criteria proposed for diagnosing VAP in clinical 
settings, such as clinical manifestations, imaging, bronchoalveolar specimens and others, 
but none of these has the needed sensitivity and specificity to accurately diagnosed VAP. 
As a result, there is still lack of acceptable gold standard in diagnostic criterion for VAP. 
The lacking of gold standard diagnostic criteria will cause a delay in diagnosis and 
subsequently delay in initiating appropriate therapy which will cause the patients’ 
prognosis became worsen. Having say that, an inappropriate or inaccurate diagnosis will 
lead to unnecessary treatment and this will not only cause complications secondary to the 
treatment but also not economical. Therefore an accurate diagnosis for VAP is fundamental. 
 
Johanson et al. (7) in year 1972 have suggested new or progressive consolidation on chest 
radiology plus at least two of the following variables:  
1. fever greater than 38°C 
2. leukocytosis or leucopenia 
3. purulent secretions 
as a diagnosis of VAP. Although the sensitivity was only 69% and specificity 72%, this 
criteria is the most acceptable and most widely used in our country currently as it was 
recommended by the American Thoracic Society Consensus Conference on VAP.  
 
Another criterion is the National Nosocomial Infection Surveillance (NNIS) system (8). 
The NNIS system was developed in the 1970s by the Centers for Disease Control (CDC) as 
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a tool to describe the epidemiology of hospital-acquired infections. It includes radiological 
signs, clinical signs and microbiological criteria.  
1. Radiology signs    
Two or more serial chest radiographs with at least 1 of the following: 
- new or progressive and persistent infiltrate 
- consolidation   
- cavitation  
2. Clinical signs  
At least 1 of the following: 
- fever (temperature > 38 C) 
- leukopenia (< 4000 WBC) or leukocytosis (> 12000 WBC) 
- altered mental status, for adults 70 years or older, with no other recognized 
cause 
3. Microbiological criteria 
At least one of the following:  
- positive growth in blood culture not related into another source of infection 
- positive growth in culture or pleural field 
- positive quantitative culture from bronchoal aveolar lavage (> 104) or 
protected    specimen brushing (> 103) 
- five percent or more of cells with intracellular bacteria on direct microscopic 
examination of Gram-stained bronchoal aveolar lavage fluid 
- histopathological evidence of pneumonia 
Plus at least 2 of the following:- 
- new onset of purulent sputum, or change in character of sputum 
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- increased respiratory secretions, or increased suctioning requirements 
- new-onset or worsening cough, or dyspnea, or tachypnea 
- rales or bronchial sounds 
- worsening gas exchange 
- increase oxygen requirement 
This NNIS system has a slightly higher sensitivity (84% versus 69%) if compare to the 
Johanson’s recommendation but the specificity was only 69%. 
 
Pugin et al. in 1991 also developed the Clinical Pulmonary Infection Score (CPIS) which 
was based on six variables such as fever, leukocytosis, tracheal aspirates, oxygenation, 
radiographic infiltrates, and semi-quantitative cultures of tracheal aspirates with Gram stain. 
Each variable has score from 0 to 2. Total score of > 6 points suggests ventilator-associated 
pneumonia. 
1. Temperature 
- 0 point: 35.5-38.4 degree celcius 
- 1 point: 38.5-38.9 degree celcius 
- 2 point: < 36 or > 39 degree celcius 
2. Blood leukocytes (cells/µL) 
- 0 point: 4000-11000 
- 1 point: < 4000 or > 11000 
- 2 point: > 500 band form 
3. Oxygenation 
- 0 point: PaO2/FiO2 > 240 or acute respiratory distress syndrome 
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- 2 point: PaO2/FiO2 < 240 and no evidence of acute respiratory distress 
syndrome 
4. Pulmonary radiography 
- 0 point: no infiltrate 
- 1 point: diffuse or patchy infiltrate 
- 2 point: localized infiltrate 
5. Tracheal secretions (score) 
- 0 point: < 14 
- 1 point: > 14 
- 2 point: purulent secretion 
6. Culture of tracheal aspirate 
- 0 point: minimal or no growth 
- 1 point: moderate or more growth 
- 2 point: moderate or greater growth 
The initial description by Pugin (9) showed high sensitivity of 93% and specificity of 100%. 
However that sample size of the study was small and only included 28 subjects.  
Furthermore,  the CPIS was compared to quantitative culture of BAL fluid using a 'bacterial 
index' defined as the sum of the logarithm of all bacterial species recovered, which is not 
considered an acceptable gold standard for the diagnosis of VAP. Later research compared 
the CPIS with the pathological diagnosis showed that the CPIS had sensitivity between 72 
and 77% and specificity between 42 and 85%. 
 
There are also many other studies evaluated the role of bacteriological data in improving 
the accuracy of a clinical diagnosis of VAP. These studies showed that bacteriological data 
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such as bronchoalveolar lavage (BAL), protected specimen brush and tracheobronchial 
aspiration did not superior to clinical diagnosis of VAP (10-12).  However, these 
bacteriological data might be useful in identifying the infecting microorganism and assist in 
initiating the appropriate therapy.  
 
Recently, there are increasing in interest in researchers regarding the role of using 
biological markers in diagnosing VAP. The proposed pathophysiology is that when the 
protective mechanism that prevent microorganism from reaching the alveoli are 
overwhelmed, the alveolar macrophages will be activated and release all the endogenous 
mediators. Biomarkers such as C-reactive protein, procalcitonin, elastin fiber, endotoxin 
and others are being studied. C-reactive protein and procalcitonin seems like promising 
biomarkers in diagnosis of VAP while elastin fiber and endotoxin are of limited value. 
However, large scale studies are still needed in evaluating the usefulness of biological 
markers in diagnosing VAP. 
 
1.2.1.4 Prevention Strategies 
 
Base on the pathogenesis and risk factors of VAP, prevention strategies can be 
implemented to reduce the incidence of VAP. There are several preventive strategies 
introduced by multiple sites and journals. Among them are American Thoracic Society 
(ATS), New England Journal of Medicine (NEJM) and Critical Care (CC). Below are 
guidelines of VAP bundles from ATS (13). 
1. General prophylaxis 
 Effective infection control measures such as staff education and hand hygiene.  
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 Surveillance of ICU infections.  
2. Intubation and mechanical ventilation. 
 Avoid intubation and reintubation if possible. 
  Whenever possible, used noninvasive ventilation rather than invasive ventilation. 
 Orotracheal intubation and orogastric tubes are preferred over nasal tubes as nasal 
tubes can cause nosocomial sinusitis and increases risk of VAP. 
 Reduce early onset VAP by continuous suction of subglottic secretion. 
 Maintain the endotracheal cuff pressure > 20cmH2O as it will prevent bacterial 
from trackling down to the lower respiratory tract. 
 Contaminated condensate should be prevented from entering the ETT. 
 Heat moisture exchanger (HME) is not VAP prevention tools. 
 Reduce the day of intubation and early extubation if possible. 
 Adequate staffing as 1 to 1 nursing if possible. 
3. Aspiration, body position, and enteral feeding. 
 Prop up patient 30-45 degree to prevent from aspiration. 
 Enteral feeding is preferred over parenteral feeding.  
4. Modulation of colonization: oral antiseptics and antibiotics. 
 Antibiotic prophylaxis for HAP will reduce but not recommend for antibiotic if 
suspected colonization of MDR pathogens.  
 Prior systemic antibiotic will reduce the risk of nosocomial pneumonia but we 
should suspect MDR pathogen if history of prior antibiotic administration is present 
at the time of onset of infection. 
 Not recommend to use prophylactic antibiotic for 24 hours following intubation. 
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 Use of oral chlorhexidine  in post CABG patient has shown to reduce VAP but its 
routine use not recommended. 
 Sedation vacation and not using paralytic agent will preserve patient cough and gag 
reflex which is good for prevention for VAP. 
5. Stress bleeding prophylaxis, transfusion, and hyperglycemia. 
 Stress ulcer prophylaxis with either H2 antagonists or sucralfate. 
 Transfusion of packed cell should follow a protocol and leukocyte-depleted  red 
blood cell should be used in selected patient populations. 
 Maintain capillary blood sugar between 80-110mg/dl. 
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1.2.2 Bronchoscope and Bronchoscopy 
 
Bronchoscope is an endoscope specially designed for passage through the trachea to permit 
inspection of the interior of the tracheobronchial tree. We can use bronchoscope to carry 
out endobronchial diagnostic and therapeutic maneuvers such as taking specimen for 
culture and biopsy and removal of foreign bodies. Bronchoscopy is the procedure we 
perform using a bronchoscope. 
 
1.2.2.1 History of Bronchoscope 
 
Gustav Killian was the father of bronchoscope. He was born on June 2, 1860. He studied 
medicine at the University of Strassburg then continued clinical education at Freiburg, 
Berlin and Heidelberg. He became head of the section of rhinolaryngology at Freiburg later. 
In 1889, he attended a meeting of Society of South German Laryngologists in Heidelberg. 
In that meeting, he learned about Kirstein who intentionally started to intubate the larynx 
with the esophagoscope after he accidentally passed the scope in the tracheal. He also 
learned about the experiences of Krakow who introduced direct lower tracheoscopy via 
tracheostomy without any complications. Thus in 1896, he began his experimental work. 
He performed the first direct endoscopy via the larynx in a volunteer and was able to 
introduce the scope into the bronchus and bronchi until the lobar level easily. So in year 
1897, bronchoscopy was born. After he successfully removed 3 foreign bodies with his new 
direct bronchoscope, he presented his findings at the sixth meeting of the Society of South 
German Laryngologists in Heidelberg on May 29, 1898, and in the same year his first 
publication on direct bronchoscopy was printed (14).  
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During the early years, the indications for the using the bronchoscope was mainly for 
therapeutic purposes. It was used to remove foreign bodies and dilation of strictures from 
tuberculosis and diphtheria. In the early part of the 20th century, Chevalier Jackson, further 
advanced bronchoscopic techniques and designed modern rigid bronchoscopies (15). 
Fibreoptic bronchoscopy (FOB) was then developed in the late 1960s by S. Ikeda. 
 
1.2.2.2 Indications, Contraindications and Complications of Bronchoscopy 
 
Bronchoscope can be divided into rigid bronchoscope and flexible bronchoscope. Flexible 
bronchoscope nowadays gains more popularity since it was introduced in 1968. This is 
because compare to rigid bronchoscope, flexible bronchoscopes are more easily inserted, 
better tolerated by patient and can be used on critically ill patients. Furthermore, the 
flexible bronchoscope allows one to examine significantly more of the tracheobronchial 
tree including those of the upper lobes.  
 
Indications for bronchoscope can be divided into diagnostic and therapeutic purposes (16) 
For diagnostic purposes:- 
• Identify suspicious lung pathology 
• Examine patient with recurrent or persistant atelactasis 
• Assessment of airway patency  
• Investigate for hemoptysis, persistent cough, localized wheeze or stridor 
• Obtain specimens for cytologic, histologic and microbiologic evaluation such as 
for diagnosis of lung carcinoma 
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• Obtain specimen for suspicious or positive sputum cytology results 
• Identify the extend of airway injury from toxic inhalation, burn  or aspiration 
• Evaluation of problems associated with endotracheal or tracheostomy tubes such 
as tracheal damage, airway obstruction or to confirm tube placement 
For therapeutic purposes:- 
• Aspiration of retained secretions as in condition that mucus plug causing lung 
collapse or atelactasis 
• Bronchoalveaolar lavage 
• Resection of tumor by using laser 
• As one of the management of bronchopleural fistula 
• Photodynamic therapy  
• Placement of airway stent for tracheomalacia  
• For intubation in difficult situation 
• Removal of foreign body usually by using rigid bronchoscope 
 
Having discussed about the indications of bronchoscopy, we should also know about the 
contraindications for this procedure. However, until recently, there are still no control 
studies as to which factors causing patient unfit to do the bronchoscope. So we have to 
weigh the risk and benefit of doing bronchoscopy on individual patient.  
High risk for bronchoscopy:- 
• patient not cooperative 
• unstable cardiovascular disease 
• tracheal obstruction or stenosis 
• moderate to severe hypoxemia 
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• hypercapnia 
• uremia 
• immunosuppression 
• severe asthma 
• bleeding disorders or coagulopathy 
• respiratory failure  
We have to note that lack of adequate staff and facilities are also considered as 
contraindications for bronchoscopy. 
 
Bronchoscopy, particularly flexible bronchoscopy is an extremely safe procedure as long as 
we take the basic precautions. Credle Jr et al.(17) and Suratt et al. (18) reported a mortality 
rate of 0.01% and a major complication rate of 0.08% in a series of 24 521 procedures, and  
a 0.02% mortality and 0.3% major complication rate in a series of around 48 000 cases, 
respectively. Complications of bronchoscopy are divided into minor and major (19) 
Minor complications (not life threatening):- 
 vasovagal reactions 
 febrile 
 cardiac arrhythmias or dysrhythmias 
 bleeding 
 airway obstruction 
 pneumothorax 
 nausea and vomiting 
Major life threatening complications:- 
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 hypoxia or respiratory depression 
 infection to the lung or pneumonia 
 pneumothorax 
 airway obstruction 
 cardiorespiratory arrest 
 arrhythmias 
 pulmonary congestion 
  
The complications rate and whether it is a major or minor complication depend on the 
procedures and patients. For example, the transbronchial biospsy is associated with 
pneumothorax (5%) and hemorrhage (9%) (20). However the hemorrhage are usually mild 
and not life threatening. The uremic and immunosuppresed patients are also more prone to 
bleeding. Hypoxeamia are usually associated with BAL and if larger fluid volume given for 
the lavage. 
 
1.2.3 Bronchoaveolar Lavage 
 
BAL is obtained by infusion and aspiration of a sterile physiologic solution usually normal 
saline that is given through a flexible bronchoscope introduced into a bronchial subsegment 
(21). Warming the fluid to body temperature before injecting cause less irritation to the 
airway and thus reduce coughing and improves fluid recovery. Occasionally, to break up 
the thick secretions, mixture of normal saline and N acetylcysteine can be used. BAL can 
be both diagnostic and therapeutic.  
The 
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The amount of BAL fluid needed to be given for assessment of the lungs has not been 
standardized. The BAL Cooperative Group Steering Committee has recommended using 
240 ml for the evaluation of patients with interstitial lung disease. BAL for bacterial 
cultures, including patients who are mechanically ventilated, several studies showed that 
amounts of BAL fluid ranged from 100 to 150mls. Usually 50%-70% of this fluid will be 
recovered during aspiration. 
 
BAL samples cells and debris from alveolar space. In order for our specimen to be valid 
and accurate, do not do suction through the scope 1st. After we inject the fluid, suction is 
done. The 1st bit is discarded as it is highly contaminated. Then we send the remaining 
sample for anylasis.  The most accurate sample is from the middle lobe and lingual.  
 
The BAL samples from non smoker and smoker are different. The table 3 below shows the 
BAL sample for non smoker. While for smoker there are decrease in lymphocytes (less 
than 7%) and an increase in neutrophils (more than 10%) if compare to non smoker. 
 
Table 2: BAL sample for non smoker (22) 
 Normal Adults (Nonsmokers) Alveolar BAL Differential Cell Counts 
Macrophages  > 85% 
Lymphocytes (CD4+/CD8+ =  0.9–2.5)  10–15% 
Neutrophils  < 3% 
Eosinophils  < 1% 
Squamous epithelial / ciliated columnar epithelial cells  < 5% 
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There are several disorders that we can differentiate from BAL sample according to the 
increase percentage of specific BAL cells type. For examples, increase in percentage of 
lymphocytes > 15% might suggest of sarcoidosis, hypersensitivity pneumonitis, collagen 
vascular disease and lypmhoproliferative disorder. Increase in eosinophils can be seen in 
asthma, bronchitis, bacteria, fungal and pneumocystic infections, while increase in 
neutrophils >3% might be caused by aspiration pneumonia, bacterial and fungal infection 
and ARDS. 
 
Beside from the normal cells, we can also obtain some abnormal findings from BAL. Some 
diagnosis also can be derived from these findings. Infectious organism cultured from BAL 
most probably is due to lower respiratory tract infection while malignant cells from BAL 
are due to cancer. Bloody fluid points to pulmonary hemorrhage or diffuse alveolar damage 
while milky fluid is caused by pulmonary alveolar proteinosis. 
 
In the absence of a gold standard for the diagnosis of VAP, the value of BAL in diagnosis 
of VAP remains controversial. However there are studies that showed in patient with 
suspected VAP, the usage of BAL to directly sample a suspected area and quantitative 
cultures to distinguish infecting microorganism from colonizing microorganisms improved 
the survival rate, decreased antibiotic use, and was associated with fewer organ failures 
(23).  Sanchez-Nieto et al. (24) reported that VAP patients who are managed with invasive 
strategy such as BAL have no significant influences on the mortality but it significantly 
modified the initial antimicrobial therapy.  
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In our ICU setting in HSB, it is difficult to adhere to invasive strategy such as BAL in all 
VAP patients as there is limited unit of FOB and not all staffs are trained in assisting 
bronchscopy. However, in this study, we used FOB for BAL sampling after the patients 
were diagnosed to have VAP. 
 
1.3 INTENSIVE CARE UNIT HOSPITAL SULTANAH BAHIYAH 
 
In this study, we take ICU HSB as having 24 beds (12 beds from ICU; 12 from high 
dependency ward (HDW) which function is exactly same as ICU). Total staff nurses are 83 
(43 from ICU and 40 from HDW). There are 3 shift per day; AM shift which is from 7am-
2pm, PM shift from 2-9pm and night shift 9pm to 7am. There are 16 staff nurses per shift 
(8 in ICU and HDW each). Each staff nurse will be assign to 1 to 2 patients depends on the 
severity of illnesses of the patients’ in charge.  
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1.4 METHODOLOGY 
 
1.4.1 Study Type 
This is an observational study. 
 
1.4.2 Study Design 
This was a prospective, cohort study. The primary end point was to determine the 
prevalence of VAP in ICU HSB. The other objectives were the risk factors for VAP and the 
identification of organism involved in VAP. 
 
1.4.3 Study Setting 
This study was conduct in Intensive Care Units Hospital Sultanah Bahiyah. 
 
1.4.4 Study Period 
The duration of study was 12 months, started from 1st August 2014 to 31st July 2015. 
 
1.4.5 Study Population 
The study population was patients admitted to ICU HSB during the study period and who 
fulfill the inclusion and exclusion criteria.  
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1.4.6 Diagnosis  
 
In Hospital Sultanah Bahiyah, Alor Setar, Kedah, the diagnosis criteria for VAP is based on 
MRIC. It is a modified version of those mentioned above based on the combination of 
clinical manifestation, imaging and laboratories results. (Appendix I) 
 Diagnosis of VAP based on  
(i) Suspicion of VAP 
(ii) Chest X-rays shows new and or progressive pulmonary infiltrates  
(iii) Presence of either 2 of the following 4 criteria 
 Fever > 38.5oC or  < 36oC within 24 hours 
 Total white cell count >12 000/mm3 within 24 hours 
 Purulent tracheobronchial secretions within 24 hours 
 Reduction of PaO2/FiO2 > 15% in the last 48 hours 
 
1.4.7 Selection Criteria 
 
1.4.7.1 Inclusion Criteria 
 
 Intubated patient  
 Admitted to ICU 
 Age more or equal to 12 years old 
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1.4.7.2 Exclusion Criteria 
 
 Intubated less than 48 hours 
 Patients that planned for end of life care 
 
1.4.8 Sample Size Calculation 
 
Sample size calculation was guided by Encik Shahrul Aiman Bin Soelar, statistician in Clinical 
Research Center (CRC) HSB Alor Setar. We used the calculator by Niang L, Winn T, Rusdi BN. 
Sample Size Calculator for Prevalence Studies, Version 1.0.01, (25) which is available at the below 
link. Http: // www.kck.usm.my/ppsg/statistical_resources/SSCPSversion1001.xls. The formula is as 
below.  
Formula without Finite Population Correction 
n = Z2P (1-P) / d2 
 
Where 
n = sample size 
Z = statistic for a level of confidence 
P = expected prevalence or proportion (if the expected prevalence is 20%, then P = 0.2) 
d = precision (if the precision is 5%, then d = 0.05) 
 
Formula with Finite Population Correction 
n’ = NZ2P (1-P) / d2 (N-1) + Z2P (1-P) 
